Cerep Moves Beyond Services
Can slow and steady win the drug-discovery race? France's Cerep prepares to find out, as it pushes past its fee-for-service start.
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.